Top Tweets for #HeartTX

12 days ago

In the Spanish national transplant registry, heart transplant incidence with donor older than recipient increased from 7% in 1995-1999 to 29% in 2015-2019 with no effect in short-, medium-, and long-term survival with age differences up 20 years. #HeartTx 🔗: https://t.co/rfytMu8XIt

1

10

5

1K

20 days ago

Among middle aged, older adults with advanced HF, #Hearttx offered better 2-year survival than HM3. Outcomes shifted toward HM3 when waitlist time was included, highlighting importance of real-world treatment pathways, timing. https://t.co/abJan3hGCL #JACCHF #HeartFailure #LVAD

JACCJournals's tweet photo. Among middle aged, older adults with advanced HF, #Hearttx offered better 2-year survival than HM3. Outcomes shifted toward HM3 when waitlist time was included, highlighting importance of real-world treatment pathways, timing.

https://t.co/abJan3hGCL

#JACCHF #HeartFailure #LVAD https://t.co/foT1H8VP4J

0

29

8

6

4K

30 days ago

Among middle-aged & older adults w/ advanced #HeartFailure, HT offered better 2yr survival than HM3. Outcomes shifted toward HM3 when waitlist time was included, highlighting the importance of real-world treatment pathways & timing https://t.co/abJan3hGCL #JACCHF #LVAD #HeartTx

JACCJournals's tweet photo. Among middle-aged & older adults w/ advanced #HeartFailure, HT offered better 2yr survival than HM3. Outcomes shifted toward HM3 when waitlist time was included, highlighting the importance of real-world treatment pathways & timing https://t.co/abJan3hGCL

#JACCHF #LVAD #HeartTx https://t.co/TXFrM4ifv7

1

19

11

9

4K

about 1 month ago

Now in #JACCHF, new work from the Donor Heart Study on classification of donors with LVH, opportunities to reclassify using geometric remodeling, leaving a path forward to accept more donors for listed patients https://t.co/yRzVQ1xpjI #Hearttx @KiranKhush1 @Stanford_HF

JACCJournals's tweet photo. Now in #JACCHF, new work from the Donor Heart Study on classification of donors with LVH, opportunities to reclassify using geometric remodeling, leaving a path forward to accept more donors for listed patients https://t.co/yRzVQ1xpjI

#Hearttx @KiranKhush1 @Stanford_HF https://t.co/0msxXuW5AX

0

22

8

9

5K

about 2 months ago

In re-HT recipients, SHKT was associated with sustained 10-year survival benefit and favorable renal trajectories, particularly in patients with moderate to severe renal dysfunction. These findings support dual-organ allocation https://t.co/sbgMpYnsek #JACCHF #HeartTx

JACCJournals's tweet photo. In re-HT recipients, SHKT was associated with sustained 10-year survival benefit and favorable renal trajectories, particularly in patients with moderate to severe renal dysfunction. These findings support dual-organ allocation https://t.co/sbgMpYnsek #JACCHF #HeartTx https://t.co/HgKOhyai07

1

14

2

7

4K

about 2 months ago

#ISHLTResearchGrants can further your research career. 🔎💡 Join the ranks of past grant recipients by applying for one of the 3️⃣ open grants. 📅 You have until 30 September to apply! #ISHLT #HeartTx #LungTx #Biomarkers #EVLP

1

2

1

0

534

2 months ago

#ISHLTenEspañol seminario web el próximo mes ⏰ #NRP #HeartTx #LungTx

3 months ago

📌 Webinar de #ISHLTenEspañol: Perfusión Regional Normotérmica: Presente, Futuro y Retos⠀ 🗓️ 10 de Septiembre⠀ 🔗 Ver el programa y regístrate ahora: https://t.co/ILnmoLvSoh #NRP #HeartTx #LungTx

ISHLT's tweet photo. 📌 Webinar de #ISHLTenEspañol: Perfusión Regional Normotérmica: Presente, Futuro y Retos⠀
🗓️ 10 de Septiembre⠀
🔗 Ver el programa y regístrate ahora: https://t.co/ILnmoLvSoh

#NRP #HeartTx #LungTx https://t.co/vvrWjnpnQL

0

1

0

875

0

4

2

0

577

3 months ago

On today's #JHLTpodcast, John Trahanas of @VUmedicine discusses how 10°C static cold storage—instead of ice—affected patient outcomes after #HeartTx, including improvements in #PGD and survivability.

TheJHLT's tweet photo. On today's #JHLTpodcast, John Trahanas of @VUmedicine discusses how 10°C static cold storage—instead of ice—affected patient outcomes after #HeartTx, including improvements in #PGD and survivability. https://t.co/sZ7KdN4sMq

1

3

0

362

3 months ago

Apply to the ISHLT #InternationalVisitingScholarship to exchange knowledge of #HeartTx and #LungTx and build relationships between individuals, institutions, and counties.🌍 Up to 5️⃣ scholarships are available. Learn more at 🔗https://t.co/gLvdf7aHW5

ISHLT's tweet photo. Apply to the ISHLT #InternationalVisitingScholarship to exchange knowledge of #HeartTx and #LungTx and build relationships between individuals, institutions, and counties.🌍 Up to 5️⃣ scholarships are available. Learn more at 🔗https://t.co/gLvdf7aHW5 https://t.co/PTcwrYcJwD

0

4

1

3

451

4 months ago

Want to learn new techniques in the clinic, operating room, or laboratory or experience how others deal with challenging problems with #HeartTx or #LungTx? ➡️ Apply to the #InternationalVisitingScholarship. 🌍 Up to 5️⃣ scholarships are available: 🔗 https://t.co/gLvdf7aHW5

ISHLT's tweet photo. Want to learn new techniques in the clinic, operating room, or laboratory or experience how others deal with challenging problems with #HeartTx or #LungTx? ➡️ Apply to the #InternationalVisitingScholarship. 🌍 Up to 5️⃣ scholarships are available: 🔗 https://t.co/gLvdf7aHW5 https://t.co/vaCTOwYAVr

0

7

1

0

835

5 months ago

Behind every pediatric #hearttx is a child who first has to survive long enough to receive one. The EXCOR Active Driver demonstrated excellent reliability, with 98.1% 90-day survival in the continued access cohort. https://t.co/kiM8dzGzKR #JACC #CHD #cvPed @ACTION4HF

JACCJournals's tweet photo. Behind every pediatric #hearttx is a child who first has to survive long enough to receive one.

The EXCOR Active Driver demonstrated excellent reliability, with 98.1% 90-day survival in the continued access cohort. https://t.co/kiM8dzGzKR

#JACC #CHD #cvPed @ACTION4HF https://t.co/WbobJRTWet

0

11

4

2

4K

5 months ago

#ISHLT announced $400,000 USD in grants funded by the #ISHLTFoundation. These grants fund research in #AI #biomarkers in #HeartTransplantation, #Pediatric #HeartTx, extracorporeal photopheresis immunodulation (#ECP), and innovative projects led by trainees. Congratulations to the grant recipients! 🎉🫀🫁

ISHLT's tweet photo. #ISHLT announced $400,000 USD in grants funded by the #ISHLTFoundation. These grants fund research in #AI #biomarkers in #HeartTransplantation, #Pediatric #HeartTx, extracorporeal photopheresis immunodulation (#ECP), and innovative projects led by trainees. Congratulations to the grant recipients! 🎉🫀🫁

1

10

4

1

756

6 months ago

On #JHLTThePodcast, Jon Kobashigawa @CedarsSinai shares an important update to a keystone document—the @ISHLT Consensus Conference on #GraftDysfunction Within the First 72 Hours After #HeartTx." #PGD #PrimaryGraftDysfunction #HTX

TheJHLT's tweet photo. On #JHLTThePodcast, Jon Kobashigawa @CedarsSinai shares an important update to a keystone document—the @ISHLT Consensus Conference on #GraftDysfunction Within the First 72 Hours After #HeartTx."

#PGD #PrimaryGraftDysfunction #HTX https://t.co/qulnb5geMC

1

9

5

523

6 months ago

Contemporary data suggest that durable #LVAD therapy may offer survival outcomes comparable to #HeartTx in adults <50 yrs of age. These findings support the consideration of an LVAD-first strategy in selected patients. https://t.co/0Zjd3fq2yl #JACCHF

JACCJournals's tweet photo. Contemporary data suggest that durable #LVAD therapy may offer survival outcomes comparable to #HeartTx in adults <50 yrs of age. These findings support the consideration of an LVAD-first strategy in selected patients. https://t.co/0Zjd3fq2yl #JACCHF https://t.co/ih5bKOUUP0

1

26

9

12

4K

7 months ago

Moderate, controlled hypothermic preservation using SCTS significantly improves #HeartTx outcomes and 2-year survival. The first study of any advanced heart preservation method to show a major impact on survival rates. @ParagonixSherpa 🔗: https://t.co/jgID8KmiyB

2

7

3

2

723

7 months ago

The 2026 ISHLT Consensus Statement for cardiac #xenotransplantation: the scientific, clinical, and regulatory blueprint, moving pig-to-human #HeartTx from possibility to disciplined progress, carefully, ethically, and globally. 🔗: https://t.co/6EkERbZDFB

TheJHLT's tweet photo. The 2026 ISHLT Consensus Statement for cardiac #xenotransplantation: the scientific, clinical, and regulatory blueprint, moving pig-to-human #HeartTx from possibility to disciplined progress, carefully, ethically, and globally.

🔗: https://t.co/6EkERbZDFB https://t.co/B385B0p9LL

0

7

3

4

417

7 months ago

Attend the #ISHLTraineeWorkshop in Toronto. 💡 📅 Tuesday, 21 April ➡️ Explore the program + register: 🔗 https://t.co/jhwPjzz0io 🏠 All registrants will be reimbursed for a one-night hotel stay. #EarlyCareer #HeartTx #LungTx #transplantation #ISHLT2026

1

3

1

0

459

7 months ago

Hemodynamics help inform #HeartTx listing risk & strategies. In this SRTR analysis, @MarkBelkinMD @JonGrinsteinMD & team evaluated the association between hemodynamic at listing with waitlist removal. API, LVSWI, MPS, PCWP, & SBP were the strongest predictors. 🔗: https://t.co/ij85BSPkXc

TheJHLT's tweet photo. Hemodynamics help inform #HeartTx listing risk & strategies. In this SRTR analysis, @MarkBelkinMD @JonGrinsteinMD & team evaluated the association between hemodynamic at listing with waitlist removal.

API, LVSWI, MPS, PCWP, & SBP were the strongest predictors.

🔗: https://t.co/ij85BSPkXc

1

19

7

5

2K